Standardizing minimal residual disease (MRD) assessment in lymphoid malignancies using NGS
sponsored by Adaptive Biotechnologies
Wednesday November 4th
Available through Adaptive Biotechnologies, the FDA-cleared clonoSEQ® Assay is a highly sensitive, specific, and standardized method for detecting and monitoring minimal residual disease (MRD) in patients with chronic lymphocytic leukemia, multiple myeloma or B-cell acute lymphoblastic leukemia. Learn how advances in chemistry, bioinformatics, and NGS have changed the approach to MRD monitoring in patients with lymphoid malignancies.
Available by prescription use only. For more information about the FDA-cleared uses of clonoSEQ including sample types and test limitations visit clonoSEQ.com/technical-summary
Learning Objectives:
- Compare and contrast NGS with other methodologies to measure MRD
- Understand how clonoSEQ® can identify and track MRD to aid in clinical management decisions for patients with lymphoid malignancies
- Review single-institution experience across disease spectrum including chronic lymphocytic leukemia multiple myeloma, and B-cell acute lymphoblastic leukemia
Join us and you will:
- Be able to compare and contrast NGS with other methodologies to measure MRD
- Understand how clonoSEQ® can identify and track MRD to aid in clinical management decisions for patients with lymphoid malignancies
- Review single-institution experiences across the disease spectrum, including chronic lymphocytic leukemia, multiple myeloma, and B cell acute lymphoblastic leukemia
